Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
about
Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement componentsThe StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cellsDysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation siteClusters of intragenic Alu repeats predispose the human C1 inhibitor locus to deleterious rearrangementsType II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor geneType I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exonNonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edemaC1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational diseaseOtogelin: a glycoprotein specific to the acellular membranes of the inner earBIOLOGICAL ACTIVITIES OF C1 INHIBITORIdentification of candidate coding region single nucleotide polymorphisms in 165 human genes using assembled expressed sequence tagsHydrodynamic data show that C1- inhibitor of complement forms compact complexes with C1-r and C1-s.Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.C1-inhibitor: an anti-inflammatory reagent with therapeutic potential.A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.Clinical management of hereditary angio-oedema in children.Computational prediction of O-linked glycosylation sites that preferentially map on intrinsically disordered regions of extracellular proteins.Ecallantide for the treatment of hereditary angiodema in adults.Efficient detection of point mutations on color-coded strands of target DNA.Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedemaProtection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema.Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety.A Nationwide Study of Norwegian Patients with Hereditary Angioedema with C1 Inhibitor Deficiency Identified Six Novel Mutations in SERPING1.Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodemaUnmasking Heavily O-Glycosylated Serum Proteins Using Perchloric Acid: Identification of Serum Proteoglycan 4 and Protease C1 Inhibitor as Molecular Indicators for Screening of Breast Cancer.Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor.A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema.alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema.N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice.Detailed physical map of human chromosomal region 11q12-13 shows high meiotic recombination rate around the MEN1 locus.Structural comparisons of the native and reactive-centre-cleaved forms of alpha 1-antitrypsin by neutron- and X-ray-scattering in solution.Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.Genetics of Hereditary Angioedema Revisited.HAE Pathophysiology and Underlying Mechanisms.The Story of Angioedema: from Quincke to Bradykinin.Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.
P2860
Q21090813-EA96871A-FB32-4D29-9473-999BF8FA52D8Q24519797-B9E38298-7B4B-43E8-9489-F7223328B30BQ24557433-72931661-EE68-42FC-BAB6-2695F9F3C265Q24558897-836915EB-2F8A-4F96-BAA4-93893EE7EA5FQ24559923-70876CA0-DC7A-4454-AE93-36D933BC8F08Q24624048-7A94DB9B-906A-42AC-B491-26B105DA29E4Q24632004-3C051A31-334B-432B-8844-6A1BB769D075Q27644724-DE19FE45-5F9B-48FD-9496-36AB96EA050DQ28588114-559D88A7-5DF3-407D-94D0-2D72BF95810DQ28972362-540722AD-E11A-4340-9965-420FC9B42681Q33179190-E9177E9E-C63A-4555-A04A-F3DFDB51CC16Q34135731-AEBD0501-5FA0-4236-85F4-76FDD57404A5Q34195958-4EA829CB-F43B-4F68-9A3B-EBAAE00808D6Q34388554-1CF21250-D704-4F02-BC7C-25D42806380DQ34560623-5E38E172-9DE0-428F-9FDA-5D149D195293Q34764718-47C8D1A1-A2F3-4C00-8C8D-67748895CD13Q35002236-F44DE791-72EC-4CF7-9654-864C3408153AQ35046998-038DE531-95D6-4974-885B-1AD20B0E1995Q35079578-8E6A80B7-5834-4D6D-9475-63D23EB95D01Q35164437-63687F59-2498-4FA2-8701-12D6C2CBEB53Q35577711-BDCAB75B-DDC5-40CE-B762-0EFC513F21B1Q35583077-E86A7F2B-AF42-4AAE-834F-E3B4FC11CDDAQ35683784-53AECD00-A56A-48A2-90AE-5E9D24979C94Q35686053-C9687DE6-02EE-4792-A4A9-7A88A53FACF8Q35881940-BF4F022B-EA4E-4C2B-887F-53A86B20BFC9Q35927365-63715AF3-B8FA-4B1F-857D-7A2B6444AADDQ36036832-C37377E6-B048-4605-8894-0C8E07F25969Q36437568-4D30EF57-064D-47E6-B225-59D14C91CBCAQ36639349-0EEA70C6-C878-42F0-9E93-F6CFDA616868Q37013040-B10F8068-5F37-48F2-B443-16D79B50FB7AQ37116328-A4B28F5A-6430-4D63-8ABD-57043F533854Q37631785-5D0BC40E-E335-43A4-A4AC-EC13DC8912F9Q38341345-AA48041C-07F1-4763-93B2-B1348D6929BDQ38351120-53372ADF-B215-4233-8115-A26AEF6E8B1AQ38354158-3BCCD082-BC7C-4C87-B041-F78D46EB6FEAQ38619062-4AF61EE5-0721-4DAA-A8AE-B7E8722B854EQ38818135-0E88CCAF-F4F3-447E-84FF-F81EA6F21138Q38837708-BAD88CE8-6DF0-4607-89EC-2F24D9E66CD2Q38855032-296733CD-D838-4FFD-BA88-8C076C1492F8Q38912052-D50C7D8E-B0E7-4E3B-8A26-510E9B33BD5A
P2860
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
description
1986 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1986
@ast
im Juli 1986 veröffentlicher wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1986/07/29)
@sk
vědecký článek publikovaný v roce 1986
@cs
wetenschappelijk artikel (gepubliceerd op 1986/07/29)
@nl
наукова стаття, опублікована в липні 1986
@uk
مقالة علمية (نشرت في 29-7-1986)
@ar
name
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@ast
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@en
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@nl
type
label
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@ast
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@en
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@nl
prefLabel
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@ast
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@en
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@nl
P2093
P356
P1433
P1476
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
@en
P2093
E. Nielsen
E. Radziejewska
H. C. Thøgersen
J. Marrinan
R. L. Eddy
S. C. Bock
V. H. Donaldson
P304
P356
10.1021/BI00363A018
P407
P577
1986-07-29T00:00:00Z